Stock Events

Stock Events

NovoCure 

M$275.39
142
+M$0+0% Monday 18:11

Statistics

Day High
275.39
Day Low
275.39
52W High
2,140.47
52W Low
275.39
Volume
0
Avg. Volume
150
Mkt Cap
30.84B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-12.48
-10.2
-7.92
-5.64
Expected EPS
-7.067362790400001
Actual EPS
N/A

Financials

-28.01%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
24.09BRevenue
-6.75BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCRN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. provides medical devices in orthopedics, a different approach but still in the competitive landscape of comprehensive cancer care solutions.
Intuitive Surgical
ISRG
Mkt Cap189.4B
Intuitive Surgical, Inc. offers robotic-assisted surgical systems, indirectly competing with NovoCure by providing alternative cancer treatment methods.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc offers medical technologies, services, and solutions, including cancer treatments, competing in the broader oncology market.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties, including oncology.
Stryker
SYK
Mkt Cap136.19B
Stryker Corporation specializes in medical technologies, including surgical equipment and neurotechnology products that can be used in cancer treatments.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. is a research-based biopharmaceutical company with a strong portfolio in oncology, directly competing in the cancer treatment market.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is known for its pharmaceutical products for treating cancer, making it a competitor in the oncology sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a global biopharmaceutical company with a broad range of oncology treatments, competing in the cancer care market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the health care field, including cancer treatments.

About

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Show more...
CEO
ISIN
JE00BYSS4X48

Listings

F
DE
038.F
MX
MX
NVCRN.MX
XNAS
US
NVCR
SA
BR
N2VC34.SA

0 Comments

Share your thoughts

FAQ

What is NovoCure stock price today?▼
The current price of NVCRN.MX is M$275.39 MXN — it has increased by +0% in the past 24 hours. Watch NovoCure stock price performance more closely on the chart.
What is NovoCure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NovoCure stocks are traded under the ticker NVCRN.MX.
What is NovoCure market cap?▼
Today NovoCure has the market capitalization of 30.84B
When is the next NovoCure earnings date?▼
NovoCure is going to release the next earnings report on February 26, 2026.
What were NovoCure earnings last quarter?▼
NVCRN.MX earnings for the last quarter are -6.11 MXN per share, whereas the estimation was -7.78 MXN resulting in a +21.37% surprise. The estimated earnings for the next quarter are N/A MXN per share.
What is NovoCure revenue for the last year?▼
NovoCure revenue for the last year amounts to 24.09B MXN.
What is NovoCure net income for the last year?▼
NVCRN.MX net income for the last year is -6.75B MXN.
When did NovoCure complete a stock split?▼
NovoCure has not had any recent stock splits.